Engineered Immune Cells as Highly Sensitive Cancer Diagnostics

Nature Biotechnology 37, 531–539 (2019)

Amin Aalipour, Hui-Yen Chuang, Surya Murty, Aloma L. D’Souza, Seung-min Park, Gunsagar S. Gulati, Chirag B. Patel, Corinne Beinat, Federico Simonetta, Ivana Martinić, Gayatri Gowrishankar, Elise R. Robinson, Eamon Aalipour, Zahra ZhianSanjiv S. Gambhir


Endogenous biomarkers remain at the forefront of early disease detection efforts, but many lack the sensitivities and specificities necessary to influence disease management. Here, we describe a cell-based in vivo sensor for highly sensitive early cancer detection. We engineer macrophages to produce a synthetic reporter on adopting an M2 tumor-associated metabolic profile by coupling luciferase expression to activation of the arginase-1 promoter. After adoptive transfer in colorectal and breast mouse tumor models, the engineered macrophages migrated to the tumors and activated arginase-1 so that they could be detected by bioluminescence imaging and luciferase measured in the blood. The macrophage sensor detected tumors as small as 25–50 mm3 by blood luciferase measurements, even in the presence of concomitant inflammation, and was more sensitive than clinically used protein and nucleic acid cancer biomarkers. Macrophage sensors also effectively tracked the immunological response in muscle and lung models of inflammation, suggesting the potential utility of this approach in disease states other than cancer.

Read more:



User Rating: 5 ( 1 votes)

Related Articles

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker